This company has positioned itself as the logistics operator for the distribution of the Pfizer / BioNTech vaccine in Mexico, of which the first shipment arrived on December 23 and of which almost 97,000 doses had been delivered to the Mexican government as of Tuesday.
The contract for Mexico is for 34 million doses of Pfizer / BioNTech, but the government itself has accelerated the approval processes for other pharmaceutical companies, such as the Oxford / AstraZeneca vaccine, which has already obtained it, and is soon to do the same with CanSino Biologics. In its study Providing Resilience to the Pandemic, DHL states that the adequacy of the archetypes it has developed will vary depending on temperature requirements, transport distances and volumes, as well as factors related to costs, delivery times expected, storage capacity and availability of packaging and equipment. "All these parameters may vary for each vaccine and should be taken into account when selecting the most suitable archetype for distribution," the document reads.
Direct delivery. The fastest and most direct shipment of all distribution archetypes takes vaccines (palletized or boxed) directly from the filling and finishing point to the final destination by truck or air cargo. This modality would be useful in the initial global distribution for use in the first line, in the long term in small regions or in cases where the destination point is relatively close to the point of manufacture. Local cross docking. In this archetype, pallets with package-size refrigerated boxes are flown to the destination country, where they undergo cross docking, are tagged, and then trucked to different end points. This distribution solution can minimize cross-border shipping costs and works especially well for destinations in a small region that are relatively far from the point of manufacture.
Local storage. This distribution archetype uses local warehousing and execution capabilities to receive full pallets and then separate into package-size units for storage and subsequent last-mile delivery. This could be the most suitable archetype for large target regions and a long-term solution for vaccine types that can be shipped with less stringent temperature requirements. The DHL study refers to the fact that while pharmaceutical production takes place primarily in countries with a modern and intact logistics infrastructure, distribution cannot be limited to those regions. As temperature requirements will likely be the main obstacle, regions with an especially hot climate and those with limited cold chain logistics infrastructure will pose the greatest challenge in a restrictive vaccine distribution scenario.
Likewise, he mentions, national logistical capacities should be taken into account when addressing globally the local distribution of vaccines. Especially in restrictive logistics scenarios that require dry ice for refrigeration, bottlenecks may occur at destination due to centralized production of dry ice, especially if it has to be replenished every 3-5 days. But he also refers that running the last mile with conventional transport requirements (assuming a sufficient useful life at + 2–8 ° C) is much more feasible, and allows a more effective distribution to end users globally, since transport You can draw on available skills and abilities and build on previous experience and knowledge in this field.
“All rights reserved. The literary works on Cargoquin website are property of their respective owners and are displayed for informative purposes only.”